Access to Benzathine Penicillin G Treatment for Persons With Syphilis, Maricopa County, Arizona, 2021.
Sex Transm Dis
; 51(3): 192-198, 2024 Mar 01.
Article
en En
| MEDLINE
| ID: mdl-38412466
ABSTRACT
BACKGROUND:
As the incidence of syphilis continues to increase, examining benzathine penicillin G (BPG) treatment data provides valuable insight for public health strategies. This study analyzed the trends of where BPG is administered relative to the initial clinical site of syphilis diagnosis. Our findings are timely in the context of recent national BPG shortages.METHODS:
The analysis included persons diagnosed with any syphilis stage in Maricopa County, Arizona, from January 1, 2021, to December 31, 2021. The Arizona surveillance database (PRISM) was the source of demographic, testing, and treatment data.RESULTS:
Of a total of 4028 persons with syphilis, 3038 (75.4%) received at least 1 injection of BPG. Among persons who received an initial BPG injection, only 1719 (56.6%) were diagnosed and treated at the same clinical site type. The Maricopa County Sexually Transmitted Disease Clinic administered BPG to 48.8% (n = 1483) of persons with syphilis who received an initial injection.CONCLUSIONS:
Our findings analyze trends in BPG administration that are likely due to treatment referral practices and medication cost. Administration of BPG is not guaranteed at the clinical site of diagnosis, highlighting concerns regarding access to BPG. A burden is placed on patients who are required to leave their diagnosing provider to seek syphilis treatment at other health facilities that administer BPG.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Penicilina G Benzatina
/
Sífilis
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Sex Transm Dis
Año:
2024
Tipo del documento:
Article